Your browser doesn't support javascript.
loading
A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors.
Tsuji, Kohei; Hymel, David; Burke, Terrence R.
Affiliation
  • Tsuji K; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, 21702 USA. burkete@mail.nih.gov.
Anal Methods ; 12(36): 4418-4421, 2020 09 28.
Article in En | MEDLINE | ID: mdl-32970049
ABSTRACT
Using a probe consisting of a fluorescein-labeled variant of the potent polo-like kinase 1 (Plk1) inhibitor BI2536 [FITC-PEG-Lys(BI2536) 4], we were able to determine half maximal inhibitory concentration (IC50) of ATP-competitive Type 1 inhibitors of Plk1 by means of a fluorescence recovery assay. This methodology represents a cost-effective and simple alternative to traditional kinase assays for initial screening of potential Plk1 inhibitors.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Serine-Threonine Kinases / Cell Cycle Proteins Language: En Journal: Anal Methods Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Serine-Threonine Kinases / Cell Cycle Proteins Language: En Journal: Anal Methods Year: 2020 Document type: Article